Log in
NASDAQ:EYES

Second Sight Medical Products Stock Forecast, Price & News

$0.88
+0.02 (+2.34 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.82
Now: $0.88
$0.88
50-Day Range
$0.73
MA: $0.85
$1.03
52-Week Range
$0.69
Now: $0.88
$7.60
Volume162,756 shs
Average Volume518,912 shs
Market Capitalization$20.25 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.
Read More
Second Sight Medical Products logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYES
CUSIPN/A
Phone818-833-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.38 million
Book Value$0.47 per share

Profitability

Net Income$-33,590,000.00
Net Margins-994.14%

Miscellaneous

Employees123
Market Cap$20.25 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$0.88
+0.02 (+2.34 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

How has Second Sight Medical Products' stock been impacted by Coronavirus (COVID-19)?

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EYES shares have decreased by 75.2% and is now trading at $0.8761.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Second Sight Medical Products?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Second Sight Medical Products
.

When is Second Sight Medical Products' next earnings date?

Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Second Sight Medical Products
.

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products Inc (NASDAQ:EYES) announced its earnings results on Thursday, August, 13th. The medical device company reported ($0.15) earnings per share (EPS) for the quarter. Second Sight Medical Products had a negative net margin of 994.14% and a negative return on equity of 470.66%.
View Second Sight Medical Products' earnings history
.

What price target have analysts set for EYES?

2 brokers have issued 1-year price objectives for Second Sight Medical Products' shares. Their forecasts range from $2.00 to $2.50. On average, they anticipate Second Sight Medical Products' share price to reach $2.25 in the next year. This suggests a possible upside of 156.8% from the stock's current price.
View analysts' price targets for Second Sight Medical Products
.

Are investors shorting Second Sight Medical Products?

Second Sight Medical Products saw a increase in short interest in August. As of August 31st, there was short interest totaling 611,900 shares, an increase of 18.6% from the August 15th total of 516,000 shares. Based on an average daily trading volume, of 560,800 shares, the short-interest ratio is presently 1.1 days. Approximately 4.9% of the shares of the company are short sold.
View Second Sight Medical Products' Short Interest
.

Who are some of Second Sight Medical Products' key competitors?

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), VBI Vaccines (VBIV), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Ekso Bionics (EKSO) and OrganiGram (OGI).

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the following people:
  • Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 56)
  • Mr. John T. Blake, CFO & Corp. Sec. (Age 43)
  • Mr. William Patrick Ryan, Chief Operating Officer (Age 58)
  • Gunnar Bjorg, Founder
  • Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 55)

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.23%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland.
View institutional ownership trends for Second Sight Medical Products
.

Which major investors are buying Second Sight Medical Products stock?

EYES stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Second Sight Medical Products
.

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $0.88.

How big of a company is Second Sight Medical Products?

Second Sight Medical Products has a market capitalization of $20.25 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.

What is Second Sight Medical Products' official website?

The official website for Second Sight Medical Products is www.secondsight.com.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.